| Name | Title | Contact Details |
|---|
CI Financial is an independent company offering global asset management and wealth management advisory services. We are driven by a commitment to provide individuals and institutions with the highest-quality investments and advice—and offer a comprehensive and innovative selection of strategies and services. Our employees are at the heart of everything we do. They must be comfortable in a fast-paced environment in an industry that is always changing. A healthy dose of ambition, a willingness to go the extra mile and a strong sense of camaraderie are what we look for in our team members.
ZAETHER is a digital life science consultant and outcome provider for life science leaders seeking proven solutions to known challenges in getting their life science products to market.
Purem by Eberspächer is a global leader in exhaust technology and acoustic solutions, dedicated to advancing clean and quiet mobility for both passenger cars and commercial vehicles. As part of the Eberspächer Group, the company operates around 35 manufacturing sites and 40 development facilities across four continents, employing approximately 7,500 people, with a strong focus on exhaust technology. The company specializes in emission control products, including catalytic converters, particulate filters, and complete exhaust systems designed to reduce pollutants and meet global emissions standards. Additionally, Purem offers lightweight acoustic solutions to comply with noise regulations. With three R&D centers located in Germany, the USA, and China, the company is committed to innovation, holding around 2,000 patents and utilizing advanced development processes. Purem prioritizes sustainability through the use of lightweight materials and energy-efficient manufacturing practices, aligning with its vision of driving the mobility of tomorrow.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.